ORGO
NEUTRAL
$2.6
Live
Organogenesis Holdings Inc. · NASDAQ
Target $8.0
(+207.7%)
$2.21
52W Range
$7.08
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 16, 2026
Market cap
$334.47M
P/E
16.25
ROE
9.0%
Profit margin
6.6%
Debt/Equity
0.19
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
80%
ORGO presents a stark contradiction between explosive growth and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 2/9. While the company shows massive YoY revenue (78.1%) and earnings growth (555.2%) and trades below both its Graham Number ($2.92) and Intrinsic Value ($4.72), the technical trend is severely bearish (0/100). The strong liquidity ratios and low debt/equity are offset by the poor F-Score and a 1-year price decline of nearly 40%. Consequently, the stock is a high-risk value play where growth potential is currently overshadowed by fundamental instability.
Key Strengths
Explosive YoY revenue growth of 78.10%
Massive earnings growth (555.20% YoY)
Strong gross margins (75.62%) and operating margins (28.91%)
Very low Debt/Equity ratio (0.19) and high Current Ratio (3.62)
Significant undervaluation relative to Intrinsic Value ($4.72) and Graham Number ($2.92)
Key Risks
Critically low Piotroski F-Score (2/9) indicating weak financial health trends
Severe bearish technical trend (0/100) and poor 1-year price performance (-39.8%)
High volatility in quarterly earnings surprises (ranging from -491% to +383%)
Lack of broad analyst coverage (only 1 analyst providing a target)
Poor long-term shareholder returns (5Y change of -87.9%)
AI Fair Value Estimate
Based on comprehensive analysis
$3.82
+46.9% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
45
Moderate
85
90
30
20
0
AI Verdict
Speculative Value
Key drivers: Extreme growth vs. poor fundamental health, Deep discount to intrinsic value, Strong liquidity but failing F-Score
Confidence
85%
Value
85/100
Trades at a significant discount to growth-based intrinsic value ($4.72) and defensive fair value.
Positives
- Price ($2.60) is below Graham Number ($2.92)
- Low Price/Sales (0.59)
- Low Price/Book (1.10)
Watchpoints
- Market cap is small ($0.33B), increasing volatility
Future
90/100
Growth metrics are top-tier, far exceeding sector averages.
Positives
- Triple-digit earnings growth
- Strong Q/Q revenue momentum (77.7%)
Watchpoints
- Sustainability of 500%+ earnings growth is questionable
Past
30/100
Historical price action is overwhelmingly negative.
Positives
- Recent Q/Q EPS growth of 33.3%
Watchpoints
- 5-year price collapse of 87.9%
- Consistent downward trend over the last 12 months
Health
20/100
Despite a clean balance sheet, the F-Score suggests operational health is declining.
Positives
- Low Debt/Equity (0.19)
- High Current Ratio (3.62)
Watchpoints
- Piotroski F-Score of 2/9 is a major red flag for financial deterioration
Dividend
0/100
Company is in a growth phase and does not return capital to shareholders.
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$2.6
Analyst Target
$8.0
Upside/Downside
+207.7%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ORGO and closest competitors.
Updated 2026-04-15
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ORGO
Organogenesis Holdings Inc.
Primary
|
-87.9% | +26.2% | -39.8% | -36.1% | +0.8% | +8.8% |
|
DCTH
Delcath Systems, Inc.
Peer
|
-28.7% | +68.5% | -11.4% | -10.5% | +6.0% | +4.2% |
|
CLLS
Cellectis S.A.
Peer
|
-83.4% | +71.4% | +189.7% | -12.0% | -6.7% | +6.0% |
|
KROS
Keros Therapeutics, Inc.
Peer
|
-80.9% | -70.2% | -8.5% | -28.6% | -0.6% | -6.6% |
|
LAB
Standard BioTools Inc.
Peer
|
-80.7% | -51.6% | -19.1% | -30.5% | -8.2% | -2.2% |
ORG
Organogenesis Holdings Inc.
Primary
5Y
-87.9%
3Y
+26.2%
1Y
-39.8%
6M
-36.1%
1M
+0.8%
1W
+8.8%
DCT
Delcath Systems, Inc.
Peer
5Y
-28.7%
3Y
+68.5%
1Y
-11.4%
6M
-10.5%
1M
+6.0%
1W
+4.2%
CLL
Cellectis S.A.
Peer
5Y
-83.4%
3Y
+71.4%
1Y
+189.7%
6M
-12.0%
1M
-6.7%
1W
+6.0%
KRO
Keros Therapeutics, Inc.
Peer
5Y
-80.9%
3Y
-70.2%
1Y
-8.5%
6M
-28.6%
1M
-0.6%
1W
-6.6%
LAB
Standard BioTools Inc.
Peer
5Y
-80.7%
3Y
-51.6%
1Y
-19.1%
6M
-30.5%
1M
-8.2%
1W
-2.2%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
16.25
Forward P/E
8.97
PEG Ratio
N/A
P/B Ratio
1.1
P/S Ratio
0.59
EV/Revenue
0.81
EV/EBITDA
6.06
Market Cap
$334.47M
Profitability
Profit margins and return metrics
Profit Margin
6.56%
Operating Margin
28.91%
Gross Margin
75.62%
ROE
9.04%
ROA
6.43%
Growth
Revenue and earnings growth rates
Revenue Growth
+78.1%
Earnings Growth
+555.2%
Q/Q Revenue Growth
+77.7%
Q/Q Earnings Growth
+469.5%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.19
Low debt
Current Ratio
3.62
Strong
Quick Ratio
3.13
Excellent
Cash/Share
$0.75
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.2B
Gross Margin
77.8%
Op. Margin
29.0%
Net Margin
19.4%
Total Assets
$0.6B
Liabilities
$0.2B
Equity
$0.4B
Debt/Equity
0.38x
Operating CF
$0.0B
CapEx
$-0.0B
Free Cash Flow
$0.0B
FCF Yield
88%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-07
$N/A
2026-02-26
$0.24
+14.3% surprise
2025-11-06
$0.18
+153.6% surprise
2025-08-07
$-0.06
-491.0% surprise
Healthcare Sector Comparison
Comparing ORGO against 421 companies in the Healthcare sector
(25 bullish, 134 neutral, 262 bearish)
P/E Ratio
16.25
This Stock
vs
89.02
Sector Avg
-81.7%
(Discount)
Return on Equity (ROE)
9.04%
This Stock
vs
-100.15%
Sector Avg
-109.0%
(Below Avg)
Profit Margin
6.56%
This Stock
vs
-13.63%
Sector Avg
-148.2%
(Weaker)
Debt to Equity
0.19
This Stock
vs
3.22
Sector Avg
-94.1%
(Less Debt)
Revenue Growth
78.1%
This Stock
vs
121.05%
Sector Avg
-35.5%
(Slower)
Current Ratio
3.62
This Stock
vs
4.55
Sector Avg
-20.5%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ORGO
Organogenesis Holdings Inc.
|
NEUTRAL | $334.47M | 16.25 | 9.0% | 6.6% | $2.6 | |
|
DCTH
Delcath Systems, Inc.
|
NEUTRAL | $336.0M | 138.14 | 3.0% | 3.2% | $9.67 | Compare |
|
CLLS
Cellectis S.A.
|
BEARISH | $337.99M | - | -65.3% | -84.9% | $3.36 | Compare |
|
KROS
Keros Therapeutics, Inc.
|
NEUTRAL | $341.37M | 4.87 | 19.9% | 35.7% | $11.21 | Compare |
|
LAB
Standard BioTools Inc.
|
BEARISH | $345.33M | - | -13.1% | -87.8% | $0.89 | Compare |
ORGO
Organogenesis...
NEUTRAL
Mkt Cap
$334M
P/E
16.2
ROE
9.0%
Price
$2.6
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-09 | LEIBOWITZ ARTHUR S | Director | Purchase | 5,000 | $13,405 |
| 2026-03-09 | DRISCOLL MICHAEL JOSEPH | Director | Purchase | 10,000 | $26,688 |
| 2026-02-18 | GILLHEENEY GARY S. SR. | Chief Executive Officer | Stock Award | 1,077,593 | - |
| 2026-02-18 | GILLHEENEY GARY S. SR. | Chief Executive Officer | Stock Award | 1,079,481 | - |
| 2026-02-18 | FREEDMAN LORI | Officer | Stock Award | 245,905 | - |
| 2026-02-18 | FREEDMAN LORI | Officer | Stock Award | 246,337 | - |
| 2026-02-18 | LEIBOWITZ ARTHUR S | Director | Stock Award | 48,828 | - |
| 2026-02-18 | GIACOMIN JON L | Director | Stock Award | 48,828 | - |
| 2026-02-18 | BILBO PATRICK | Chief Operating Officer | Stock Award | 259,549 | - |
| 2026-02-18 | BILBO PATRICK | Chief Operating Officer | Stock Award | 260,039 | - |
| 2026-02-18 | GROW BRIAN | Officer | Stock Award | 282,705 | - |
| 2026-02-18 | GROW BRIAN | Officer | Stock Award | 283,193 | - |
| 2026-02-18 | MONTECALVO ANTONIO S | Officer | Stock Award | 51,843 | - |
| 2026-02-18 | MONTECALVO ANTONIO S | Officer | Stock Award | 51,955 | - |
| 2026-02-18 | KORFIN MICHELE ILENE | Director | Stock Award | 48,828 | - |
LEIBOWITZ ARTHUR S
Director
2026-03-09
5,000 shares
·
$13,405
DRISCOLL MICHAEL JOSEPH
Director
2026-03-09
10,000 shares
·
$26,688
GILLHEENEY GARY S. SR.
Chief Executive Officer
2026-02-18
1,077,593 shares
GILLHEENEY GARY S. SR.
Chief Executive Officer
2026-02-18
1,079,481 shares
FREEDMAN LORI
Officer
2026-02-18
245,905 shares
FREEDMAN LORI
Officer
2026-02-18
246,337 shares
LEIBOWITZ ARTHUR S
Director
2026-02-18
48,828 shares
GIACOMIN JON L
Director
2026-02-18
48,828 shares
BILBO PATRICK
Chief Operating Officer
2026-02-18
259,549 shares
BILBO PATRICK
Chief Operating Officer
2026-02-18
260,039 shares
GROW BRIAN
Officer
2026-02-18
282,705 shares
GROW BRIAN
Officer
2026-02-18
283,193 shares
MONTECALVO ANTONIO S
Officer
2026-02-18
51,843 shares
MONTECALVO ANTONIO S
Officer
2026-02-18
51,955 shares
KORFIN MICHELE ILENE
Director
2026-02-18
48,828 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
1 analysts
BTIG
2026-03-26
Buy
Buy
BTIG
2026-02-27
Buy
Buy
BTIG
2025-12-26
Buy
Buy
BTIG
2025-12-15
Buy
Buy
BTIG
2025-11-20
Buy
Buy
Past News Coverage
Recent headlines mentioning ORGO from our newsroom.
Newest → oldest
No matching news yet.